The ubiquitin-proteasome pathway and its role in cancer

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4776-4789

  Mani, Aparna ^a   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRCA1 PROTEIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; POLYUBIQUITIN; PROTEASOME; PROTEIN P27; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; PROTEIN MDM2; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; CARCINOGENESIS; CELL CYCLE; CELL CYCLE REGULATION; CELL DEATH; COLON CANCER; DRUG TARGETING; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; UBIQUITINATION; UTERINE CERVIX CANCER; WART VIRUS; COLORECTAL TUMOR; FEMALE; GENETICS; KIDNEY TUMOR; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION; UTERINE CERVIX TUMOR;

BRCA1 PROTEIN; CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GLIOBLASTOMA; HUMANS; KIDNEY NEOPLASMS; NEOPLASMS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UTERINE CERVICAL NEOPLASMS;

EID: 23044506681     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.081     Document Type: Review

References (256)

1. Goldstein G, Scheid M, Hammerling U, et al: Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci U S A 72:11-15, 1975
2. Schoenheimer R: The Dynamic State of Body Constituents. Cambridge, MA, Harvard University Press, 1942
3. Schimke RT, Doyle D: Control of enzyme levels in animal tissues. Annu Rev Biochem 39:929-976, 1970
4. Schimke RT: The importance of both synthesis and degradation in the control of arginase levels in rat liver. J Biol Chem 239:3808-3817, 1964
5. Anfinsen CB, Steinberg D, Vaughan M: Kinetic aspects of assembly and degradation of proteins. Science 124:389-395, 1956
6. Schimke RT: Control of enzyme levels in mammalian tissues. Adv Enzymol Relat Areas Mol Biol 37:135-187, 1973
7. Schimke RT, Sweeney EW, Berlin CM: The roles of synthesis and degradation in the control of rat liver tryptophan pyrrolase. J Biol Chem 240:322-331, 1965
8. Segal HL, Matsuzawa T, Haider M, et al: What determines the half-life of proteins in vivo? Some experiences with alanine aminotransferase of rat tissues. Biochem Biophys Res Commun 36:764-770, 1969
9. Haider M, Segal HL: Some characteristics of the alanine aminotransferase- and arginase-inactivating system of lysosomes. Arch Biochem Biophys 148:228-237, 1972
10. De Duve C, Wattiaux R: Functions of lysosomes. Annu Rev Physiol 28:435-492, 1966
11. Muller M, Dubiel W, Rathmann J, et al: Determination and characteristics of energy-dependent proteolysis in rabbit reticulocytes. Eur J Biochem 109:405-410, 1980
12. Neff NT, DeMartino GN, Goldberg AL: The effect of protease inhibitors and decreased temperature on the degradation of different classes of proteins in cultured hepatocytes. J Cell Physiol 101:439-457, 1979
13. Hershko A, Tomkins GM: Studies on the degradation of tyrosine aminotransferase in hepatoma cells in culture: Influence of the composition of the medium and adenosine triphosphate dependence. J Biol Chem 246:710-714, 1971
14. Simpson MV: The release of labeled amino acids from the proteins of rat liver slices. J Biol Chem 201:143-154, 1953
15. Etlinger JD, Goldberg AL: A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci U S A 74:54-58, 1977
16. Ciechanover A, Hod Y, Hershko A: A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81: 1100-1105, 1978
17. Ciechanover A, Heller H, Elias S, et al: ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci U S A 77:1365-1368, 1980
18. Hershko A, Ciechanover A, Heller H, et al: Proposed role of ATP in protein breakdown: Conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A 77:1783-1786, 1980
19. Schlesinger DH, Goldstein G, Niall HD: The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry 14:2214-2218, 1975
20. Wilkinson KD, Urban MK, Haas AL: Ubiquitin is the ATP-dependent proteolysis factor I of rabbit reticulocytes. J Biol Chem 255:7529-7532, 1980
21. Hough R, Pratt G, Rechsteiner M: Ubiquitin-lysozyme conjugates: Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates. J Biol Chem 261:2400-2408, 1986
22. Koepp DM, Harper JW, Elledge SJ: How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97:431-434, 1999
23. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998
24. Rock KL, Goldberg AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-779, 1999
25. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533, 2001
26. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82:373-428, 2002
27. Pagano M, Benmaamar R: When protein destruction runs amok, malignancy is on the loose. Cancer Cell 4:251-256, 2003
28. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 67:425-479, 1998
29. Schwartz AL, Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50:57-74, 1999
30. Adams J: The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 29:3-9, 2003 (suppl 1)
31. Handley PM, Mueckler M, Siegel NR, et al: Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Natl Acad Sci U S A 88:258-262, 1991
32. Ozkaynak E, Finley D, Varshavsky A: The yeast ubiquitin gene: Head-to-tail repeats encoding a polyubiquitin precursor protein. Nature 312:663-666, 1984
33. Durner J, Boger P: Ubiquitin in the prokaryote Anabaena variabilis. J Biol Chem 270:3720-3725, 1995
34. Vijay-Kumar S, Bugg CE, Wilkinson KD, et al: Three-dimensional structure of ubiquitin at 2.8 A resolution. Proc Natl Acad Sci U S A 82:3582-3585, 1985
35. Wilkinson KD, Audhya TK: Stimulation of ATP-dependent proteolysis requires ubiquitin with the COOH-terminal sequence Arg-Gly-Gly. J Biol Chem 256:9235-9241, 1981
36. Chau V, Tobias JW, Bachmair A, et al: A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243:1576-1583, 1989
37. Thrower JS, Hoffman L, Rechsteiner M, et al: Recognition of the polyubiquitin proteolytic signal. Embo J 19:94-102, 2000
38. Spence J, Gali RR, Dittmar G, et al: Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 102:67-76, 2000
39. Hofmann RM, Pickart CM: Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96:645-653, 1999
40. Hicke L: Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2:195-201, 2001
41. Ciechanover A, Heller H, Katz-Etzion R, et al: Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci U S A 78:761-765, 1981
42. Cook JC, Chock PB: Isoforms of mammalian ubiquitin-activating enzyme. J Biol Chem 267:24315-24321, 1992
43. Handley-Gearhart PM, Stephen AG, Trausch-Azar JS, et al: Human ubiquitin-activating enzyme, E1: Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs. J Biol Chem 269:33171-33178, 1994
44. Stephen AG, Trausch-Azar JS, Ciechanover A, et al: The ubiquitin-activating enzyme E1 is phosphorylated and localized to the nucleus in a cell cycle-dependent manner. J Biol Chem 271:15608-15614, 1996
45. McGrath JP, Jentsch S, Varshavsky A: UBA 1: An essential yeast gene encoding ubiquitin-activating enzyme. Embo J 10:227-236, 1991
46. Haas AL, Rose IA: The mechanism of ubiquitin activating enzyme: A kinetic and equilibrium analysis. J Biol Chem 257:10329-10337, 1982
47. Sullivan ML, Vierstra RD: Cloning of a 16-kDa ubiquitin carrier protein from wheat and Arabidopsis thaliana: Identification of functional domains by in vitro mutagenesis. J Biol Chem 266:23878-23885, 1991
48. Sung P, Prakash S, Prakash L: Mutation of cysteine-88 in the Saccharomyces cerevisiae RAD6 protein abolishes its ubiquitin-conjugating activity and its various biological functions. Proc Natl Acad Sci U S A 87:2695-2699, 1990
49. Sung P, Prakash S, Prakash L: Stable ester conjugate between the Saccharomyces cerevisiae RAD6 protein and ubiquitin has no biological activity. J Mol Biol 221:745-749, 1991
50. Mathias N, Steussy CN, Goebl MG: An essential domain within Cdc34p is required for binding to a complex containing Cdc4p and Cdc53p in Saccharomyces cerevisiae. J Biol Chem 273:4040-4045, 1998
51. Deffenbaugh AE, Scaglione KM, Zhang L, et al: Release of ubiquitin-charged Cdc34-S - Ub from the RING domain is essential for ubiquitination of the SCF(Cdc4)-bound substrate Sic1. Cell 114:611-622, 2003
52. Hershko A, Heller H, Eytan E, et al: The protein substrate binding site of the ubiquitin-protein ligase system. J Biol Chem 261:11992-11999, 1986
53. Reiss Y, Heller H, Hershko A: Binding sites of ubiquitin-protein ligase: Binding of ubiquitin-protein conjugates and of ubiquitin-carrier protein. J Biol Chem 264:10378-10383, 1989
54. Huang L, Kinnucan E, Wang G, et al: Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade. Science 286:1321-1326, 1999
55. Zheng N, Wang P, Jeffrey PD, et al: Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102:533-539, 2000
56. Scheffner M, Huibregtse JM, Vierstra RD, et al: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505, 1993
57. Huibregtse JM, Scheffner M, Beaudenon S, et al: A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A 92:2563-2567, 1995
58. Scheffner M, Nuber U, Huibregtse JM: Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitm thioester cascade. Nature 373:81-83, 1995
59. Huibregtse JM, Yang JC, Beaudenon SL: The large subunit of RNA polymerase II is a substrate of the Rsp5 ubiquitin-protein ligase. Proc Natl Acad Sci U S A 94:3656-3661, 1997
60. Sudol M, Chen HI, Bougeret C, et al: Characterization of a novel protein-binding module: The WW domain. FEBS Lett 369:67-71, 1995
61. Sudol M, Bork P, Einbond A, et al: Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 270:14733-14741, 1995
62. Kay BK, Williamson MP, Sudol M: The importance of being proline: The interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14:231-241, 2000
63. Kamynina E, Debonneville C, Bens M, et al: A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel. FASEB J 15:204-214, 2001
64. Rotin D, Staub O, Haguenauer-Tsapis R: Ubiquitination and endocytosis of plasma membrane proteins: Role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J Membr Biol 176:1-17, 2000
65. Staub O, Gautschi I, Ishikawa T, et al: Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. Embo J 16:6325-6336, 1997
66. Schild L, Lu Y, Gautschi I, et al: Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. Embo J 15:2381-2387, 1996
67. Staub O, Dho S, Henry P, et al: WW domains of Nedd4 bind to the proline-nch PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. Embo J 15:2371-2380, 1996
68. Joazeiro CA, Weissman AM: RING finger proteins: Mediators of ubiquitin ligase activity. Cell 102:549-552, 2000
69. Saurin AJ, Borden KL, Boddy MN, et al: Does this have a familiar RING? Trends Biochem Sci 21:208-214, 1996
70. Fang S, Jensen JP, Ludwig RL, et al: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951, 2000
71. Honda R, Yasuda H: Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473-1476, 2000
72. Joazeiro CA, Wing SS, Huang H, et al: The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-prptein ligase. Science 286:309-312, 1999
73. Waterman H, Levkowitz G, Alroy I, et al: The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274:22151-22154, 1999
74. Deshaies RJ: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467, 1999
75. Ohta T, Michel JJ, Schottelius AJ, et al: ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 3:535-541, 1999
76. Seol JH, Feldman RM, Zachanae W, et al: Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev 13:1614-1626, 1999
77. Skowyra D, Craig KL, Tyeis M, et al: F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209-219, 1997
78. Lyapina SA, Correll CC, Kipreos ET, et al: Human CUL1 forms an evolutionary conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. Proc Natl Acad Sci U S A 95:7451-7456, 1998
79. Cenciarelli C, Chiaur DS, Guardavaccaro D, et al: Identification of a family of human F-box proteins. Curr Biol 9:1177-1179, 1999
80. Carrano AC, Eytan E, Hershko A, et al: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199, 1999
81. Montagnoli A, Fiore F, Eytan E, et al: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189, 1999
82. Nefsky B, Beach D: Pub1 acts as an E6-AP-like protein ubiquitiin ligase in the degradation of cdc25. Embo J 15:1301-1312, 1996
83. Latres E, Chiaur DS, Pagano M: The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18:849-854, 1999
84. Winston JT, Strack P, Beer-Romero P, et al: The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13:270-283, 1999
85. Tsvetkov LM, Yeh KH, Lee SJ, et al: P27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664, 1999
86. Koepp DM, Schaefer LK, Ye X, et al: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294:173-177, 2001
87. Arrigo AP, Tanaka K, Goldberg AL, et al: Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 331:192-194, 1988
88. Voges D, Zwickl P, Baumeister W: The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015-1068, 1999
89. Fujiwara T, Tanaka K, Orino E, et al: Proteasomes are essential for yeast proliferation: cDNA cloning and gene disruption of two major subunits. J Biol Chem 265:16604-16613, 1990
90. Emori Y, Tsukahara T, Kawasaki H, et al: Molecular cloning and functional analysis of three subunits of yeast proteasome. Mol Cell Biol 11:344-353, 1991
91. Heinemeyer W, Kleinschmidt JA, Saidowsky J, et al: Proteinase yscE, the yeast proteasome/multicatalytic-multifunctional proteinase: Mutants unravel its function in stress induced proteolysis and uncover its necessity for cell survival. Embo J 10:555-562, 1991
92. Lowe J, Stock D, Jap B, et al: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268:533-539, 1995
93. Peters JM, Franke WW, Kleinschmidt JA: Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 269:7709-7718, 1994
94. Ganoth D, Leshinsky E, Eytan E, et al: A multicomponent system that degrades proteins conjugated to ubiquitin: Resolution of factors and evidence for ATP-dependent complex formation. J Biol Chem 263:12412-12419, 1988
95. Kisselev AF, Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8:739-758, 2001
96. Groll M, Ditzel L, Lowe J, et al: Structure of 20S proteasome from yeast at 2.4: A resolution. Nature 386:463-471, 1997
97. Wilk S, Orlowski M: Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J Neurochem 40:842-849, 1983
98. Groll M, Bajorek M, Kohler A, et al: A gated channel into the proteasome core particle. Nat Struct Biol 7:1062-1067, 2000
99. Wenzel T, Baumeister W: Conformational constraints in protein degradation by the 20S proteasome. Nat Struct Biol 2:199-204, 1995
100. Glickman MH, Rubin DM, Coux O, et al: A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94:615-623, 1998
101. Lupas A, Koster AJ, Baumeister W: Structural features of 26S and 20S proteasomes. Enzyme Protein 47:252-273, 1993
102. Larsen CN, Finley D: Protein translocation channels in the proteasome and other proteases. Cell 91:431-434, 1997
103. Glickman MH, Rubin DM, Fried VA, et al: The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol Cell Biol 18:3149-3162, 1998
104. Deveraux Q, Ustrell V, Pickart C, et al: A 26 S protease subunit that binds ubiquitin conjugates. J Biol Chem 269:7059-7061, 1994
105. Deveraux Q, Jensen C, Rechsteiner M: Molecular cloning and expression of a 26 S protease subunit enriched in dileucine repeats. J Biol Chem 270:23726-23729, 1995
106. Akopian TN, Kisselev AF, Goldberg AL: Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum. J Biol Chem 272:1791-1798, 1997
107. Verma R, Oania R, Graumann J, et al: Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 118:99-110, 2004
108. Wenzel T, Eckerskorn C, Lottspeich F, et al: Existence of a molecular ruler in proteasomes suggested by analysis of degradation products. FEBS Lett 349:205-209, 1994
109. Bachmair A, Finley D, Varshavsky A: In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179-186, 1986
110. Kwon YT, Reiss Y, Fried VA, et al: The mouse and human genes encoding the recognition component of the N-end rule pathway. Proc Natl Acad Sci U S A 95:7898-7903, 1998
111. Reiss Y, Kaim D, Hershko A: Specificity of binding of NH2-terminal residue of proteins to ubiquitin-protein ligase: Use of amino acid derivatives to characterize specific binding sites. J Biol Chem 263:2693-2698, 1988
112. Chen Z, Hagler J, Palombella VJ, et al: Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597, 1995
113. Orford K, Crockett C, Jensen JP, et al: Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 272:24735-24738, 1997
114. Yaglom J, Linskens MH, Sadis S, et al: P34Cdc28-mediated control of Cln3 cyclin degradation. Mol Cell Biol 15:731-741, 1995
115. Lahav-Baratz S, Sudakin V, Ruderman JV, et al: Reversible phosphorylation controls the activity of cyclosome-associated cyclin-ubiquitin ligase. Proc Natl Acad Sci U S A 92:9303-9307, 1995
116. Shteinberg M, Protopopov Y, Listovsky T, et al: Phosphorylation of the cyclosome is required for its stimulation by Fizzy/cdc20. Biochem Biophys Res Commun 260:193-198, 1999
117. Rudner AD, Murray AW: Phosphorylation by Cdc28 activates the Cdc20-dependent activity of the anaphase-promoting complex. J Cell Biol 149:1377-1390, 2000
118. Kramer ER, Scheuringer N, Podtelejnikov AV, et al: Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell 11:1555-1569, 2000
119. Hershko A, Ganoth D, Sudakin V, et al: Components of a system that ligates cyclin to ubiquitin and their regulation by the protein kinase cdc2. J Biol Chem 269:4940-4946, 1994
120. Sudakin V, Ganoth D, Dahan A, et al: The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 6:185-197, 1995
121. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 234:364-368, 1986
122. Ciechanover A, Finley D, Varshavsky A: Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 37:57-66, 1984
123. Ciechanover A, DiGiuseppe JA, Bercovich B, et al: Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 88:139-143, 1991
124. Kibel A, Iliopoulos O, DeCaprio JA, et al: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446, 1995
125. Duan DR, Pause A, Burgess WH, et al: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406, 1995
126. Pause A, Lee S, Worrell RA, et al: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94:2156-2161, 1997
127. Kamura T, Koepp DM, Conrad MN, et al: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661, 1999
128. Iwai K, Yamanaka K, Kamura T, et al: Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 96:12436-12441, 1999
129. Lisztwan J, Imbert G, Wirbelauer C, et al: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833, 1999
130. George DJ, Kaelin WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349:419-421, 2003
131. Huang LE, Gu J, Schau M, et al: Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95:7987-7992, 1998
132. Salceda S, Caro J: Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642-22647, 1997
133. Pugh CW, O'Rourke JF, Nagao M, et al: Activation of hypoxia-inducible factor-1: Definition of regulatory domains within the alpha subunit. J Biol Chem 272:11205-11214, 1997
134. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741, 2000
135. Tanimoto K, Makino Y, Pereira T, et al: Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Embo J 19:4298-4309, 2000
136. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
137. Kamura T, Sato S, Iwai K, et al: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97:10430-10435, 2000
138. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472, 2001
139. Masson N, Willam C, Maxwell PH, et al: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 20:5197-5206, 2001
140. Ivan M, Kondo K, Yang H, et al: HIFalpha targeted for VHL-mediated destruction by praline hydroxylation: Implications for O2 sensing. Science 292:464-468, 2001
141. Clifford SC, Cockman ME, Smallwood AC, et al: Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038, 2001
142. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
143. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961, 2002
144. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996
145. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93:10595-10599, 1996
146. Shibata H, Toyama K, Shioya H, et al: Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278:120-123, 1997
147. Joslyn G, Carlson M, Thliveris A, et al: Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 66:601-613, 1991
148. Ichii S, Takeda S, Horii A, et al: Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). Oncogene 8:2399-2405, 1993
149. Groden J, Thliveris A, Samowitz W, et al: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589-600, 1991
150. Nishisho I, Nakamura Y, Miyoshi Y, et al: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665-669, 1991
151. Miyoshi Y, Nagase H, Ando H, et al: Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum Mol Genet 1:229-233, 1992
152. Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 359:235-237, 1992
153. Munemitsu S, Albert I, Souza B, et al: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 92:3046-3050, 1995
154. Rubinteld B, Souza B, Albert I, et al: Association of the APC gene product with beta-catenin. Science 262:1731-1734, 1993
155. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512, 1998
156. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883-2891, 1999
157. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426, 1999
158. Uthoff SM, Eichenberger MR, McAuliffe TL. et al: Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Mol Carcinog 31:56-62, 2001
159. Salic A, Lee E, Mayer L, et al: Control of beta-catenin stability: Reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol Cell 5:523-532, 2000
160. Rubinfeld B, Albert I, Porfiri E, et al: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272:1023-1026, 1996
161. Polakis P: Casein kinase 1: A Wnt'er of disconnect. Curr Biol 12:R499-R501, 2002
162. Aberle H, Bauer A, Stappert J, et al: Beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J 16:3797-3804, 1997
163. Easwaran V, Song V, Polakis P, et al: The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling. J Biol Chem 274:16641-16645, 1999
164. Hart M, Concordet JP, Lassot I, et al: The F box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207-210, 1999
165. Sparks AB, Monn PJ, Vogelstein B. et al: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130-1134, 1998
166. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79, 1990
167. Dyson N, Howley PM, Munger K, et al: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989
168. Munger K, Werness BA, Dyson N, et al: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J 8:4099-4105, 1989
169. Hainaut P, Hollstein M: p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 77:81-137, 2000
170. Heilstem M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 253:49-53, 1991
171. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
172. Fang P, Lev-Lehman E, Tsai TF, et al: The spectrum of mutations in UBE3A causing Angelman syndrome. Hum Mol Genet 8:129-135, 1999
173. Huibregtse JM, Schaffner M, Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13:4918-4927, 1993
174. Crook T, Tidy JA, Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556, 1991
175. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990
176. Li X, Coffino P: High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70:4509-4516, 1996
177. Elbel M, Carl S, Spaderna S, et al: A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 239:132-149, 1997
178. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27, 1997
179. Haupt Y, Maya R, Kazaz A, et al: Mdm2 promotes the rapid degradation of p53. Nature 387:296-299, 1997
180. Momand J, Jung D, Wilczynski S, et al: The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459, 1998
181. Leach FS, Tokino T, Meltzer P, et al: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993
182. Cordon-Cardo C, Latres E, Drobniak M, et al: Molecular abnormalities of mdrn2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994
183. Luu Y, Li G: The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU. J Invest Dermatol 119:1207-1209, 2002
184. Luu Y, Bush J, Cheung KJ Jr, et al: The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 276:214-222, 2002
185. Takimoto R, Wang W, Dicker DT, et al: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1:47-55, 2002
186. Foster BA, Coffey HA, Morin MJ, et al: Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510, 1999
187. Wang W, Takimoto R, Rastinejad F, et al: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23: 2171-2181, 2003
188. D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23-34, 2003
189. Starita LM, Parvin JD: The multiple nuclear functions of BRCA1: Transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 15:345-350, 2003
190. Lorick KL, Jensen JP, Fang S, et al: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 96:11364-11369, 1999
191. Wu LC, Wang ZW, Tsan JT, et al: Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440, 1996
192. Xia Y, Pao GM, Chen HW, et al: Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 278:5255-5263, 2003
193. Brzovic PS, Keeffe JR, Nishikawa H, et al: Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 100:5646-5651, 2003
194. Brzovic PS, Meza JE, King MC, et al: BRCA1 RING domain cancer-predisposing mutations: Structural consequences and effects on protein-protein interactions. J Biol Chem 276:41399-41406, 2001
195. Hashizume R, Fukuda M, Maeda I, et al: The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537-14540, 2001
196. Ruffner H, Joazeiro CA, Hemmati D, et al: Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 98:5134-5139, 2001
197. Williams RS, Lee MS, Hau DD, et al: Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11:519-525, 2004
198. Nishikawa H, Ooka S, Sato K, et al: Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem 279:3916-3924, 2004
199. Wu-Baer F, Lagrazon K, Yuan W, et al: The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 278:34743-34746, 2003
200. Chen A, Kleiman FE, Manley JL, et al: Autoubiquitination of the BRCATBARD1 RING ubiquitin ligase. J Biol Chem 277:22085-22092, 2002
201. Mallery DL, Vandenberg CJ, Hiom K: Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. Embo J 21:6755-6762, 2002
202. Jensen DE, Proctor M, Marquis ST, et al: BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097-1112, 1998
203. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995
204. Shirane M, Harumiya Y, Ishida N, et al: Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 274:13886-13893, 1999
205. Fero ML, Randel E, Gurley KE, et al: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180, 1998
206. Desdouets C, Brechot C: P27: A pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer. Pathol Biol (Paris) 48:203-210, 2000
207. Moller MB: P27 in cell cycle control and cancer. Leuk Lymphoma 39:19-27, 2000
208. Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10-17, 2000
209. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234, 1997
210. Kawamata N, Morosetti R, Miller CW, et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266-2269, 1995
211. Pietenpol JA, Bohlander SK, Sato Y, et al: Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995
212. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000
213. Sutterluty H, Chatelain E, Marti A, et al: P45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1:207-214, 1999
214. Hershko D, Bornstein G, Ben-Izhak O, et al: Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91:1745-1751, 2001
215. Kudo Y, Kitajima S, Sato S, et al: High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 61:7044-7047, 2001
216. Latres E, Chiarle R, Schulman BA, et al: Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 98:2515-2520, 2001
217. Gstaiger M, Jordan R, Lim M, et al: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 98:5043-5048, 2001
218. Chiarle R, Fan Y, Piva R, et al: S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 160:1457-1466, 2002
219. Zhu CQ, Blackball FH, Pintilie M, et al: Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res 10:1984-1991, 2004
220. Sugawa N, Ekstrand AJ, James CD, et al: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602-8606, 1990
221. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
222. Schmidt MH, Furnari FB, Cavenee WK, et al: Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A 100:6505-6510, 2003
223. Yokouchi M, Kondo T, Houghton A, et al: Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 274:31707-31712, 1999
224. Lee PS, Wang Y, Dominguez MG, et al: The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. Embo J 18:3616-3628, 1999
225. Miyake S, Lupher ML Jr, Druker B, et al: The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A 95:7927-7932, 1998
226. Levkowitz G, Waterman H, Zamir E, et al: C-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12:3663-3674, 1998
227. Levkowitz G, Waterman H, Ettenberg SA, et al: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029-1040, 1999
228. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, et al: Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. Embo J 17:3385-3397, 1998
229. Muthuswamy SK, Gilman M, Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19:6845-6857, 1999
230. Klapper LN, Waterman H, Sela M, et al: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388, 2000
231. Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature 401:297-300, 1999
232. Bortner DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17:453-459, 1997
233. Ohtsubo M, Theodoras AM, Schumacher J, et al: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624, 1995
234. Keyomarsi K, Conte D Jr, Toyofuku W, et al: Deregulation of cyclin E in breast cancer. Oncogene 11:941-950, 1995
235. Li JQ, Miki H, Ohmori M, et al: Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol 32:945-953, 2001
236. Erlanson M, Landberg G: Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 40:461-470, 2001
237. Hayashi H, Ogawa N, Ishiwa N, et al: High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 34:59-65, 2001
238. Donnellan R, Chetty R: Cyclin E in human cancers. FASEB J 13:773-780, 1999
239. Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997
240. Won KA, Reed SI: Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. Embo J 15:4182-4193, 1996
241. Clurman BE, Sheaff RJ, Thress K, et al: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10:1979-1990, 1996
242. Strohmaier H, Spruck CH, Kaiser P, et al: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316-322, 2001
243. Moberg KH, Bell DW, Wahrer DC, et al: Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413:311-316, 2001
244. Spruck CH, Strohmaier H, Sangfelt O, et al: HCDC4 gene mutations in endometrial cancer. Cancer Res 62:4535-4539, 2002
245. Knuutila S, Aalto Y, Autio K, et al: DNA copy number losses in human neoplasms. Am J Pathol 155:683-694, 1999
246. Pei XY, Dai Y, Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17:2036-2045, 2003
247. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849, 2002
248. Teicher BA, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645, 1999
249. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
250. Frankel A, Man S, Elliott P, et al: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728, 2000
251. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
252. Johnson TR, Stone K, Nikrad M, et al: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22:4953-4963, 2003
253. Sunwoo JB, Chen Z, Dong G, et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428, 2001
254. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappa B inhibition. Cancer Res 61:3535-3540, 2001
255. Chauhan D, Li G, Auclair D, et al: 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 9:149-155, 2004
256. Chauhan D, Li G, Shringarpure R, et al: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174-6177, 2003